Diabetes Technology & Therapeutics

Article	Citations
Impact of Sample Type on ADAP-Based Autoantibody Detection for Type 1 Diabetes Population Screening	185
New Insulins, Biosimilars, and Insulin Therapy	182
Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes	136
Statistically Adjusting for Wear Time in Randomized Trials of Continuous Glucose Monitors as a Complement to Intent-to-Treat and As-Treated Analyses: Application and Evaluation in Two Trials	129
Comparison of Cgmanalysis, a Free Open-Source Continuous Glucose Monitoring Data Management and Analysis Software, with Commercially Available CGM Platforms: Data Standardization for Diabetes Technolo	87
Glycemia Around Exercise in Adults with Type 1 Diabetes Using Automated and Nonautomated Insulin Delivery Pumps: A Switch Pilot Trial	82
Clinical Evaluation of a Novel CGM-Informed Bolus Calculator with Automatic Glucose Trend Adjustment	69
The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes	62
Is It Time to Replace Time-in-Range with Time-in-Tight-Range? Maybe Not	60
Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility Study	58
Real-Life Achievements of MiniMed 780G Advanced Closed-Loop System in Youth with Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective Trial	57
The Official Journal of ATTD Advanced Techologies & Treatments for Diabetes CONFERENCE 6–9 MARCH 2024 I FLORENCE & ONLINE	57
Letter: Response to: “Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia”	56
Practical Application of Continuous Glucose Monitoring in Clinical Practice: Case Studies	55
Disordered Eating Behaviors Among Adolescents and Young Adults with Type 1 Diabetes Treated with Insulin Pumps and Hybrid Closed-Loop Systems	54
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes	53
Letter: Tirzepatide in Type 1 Diabetic Obese Patient Using Hybrid Closed-Loop	51
A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor	51
Practical Considerations and Implementation of Automated Insulin Delivery Systems	50
Metabolic Models, in Silico Trials, and Algorithms	49
A Call-to-Action to Eliminate Barriers to Accessing Automated Insulin Delivery Systems for People with Type 1 Diabetes	48
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin	47
Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States	47
Acknowledgment of Reviewers: 2024	46
Relationship Between Moderate-to-Vigorous Physical Activity and Glycemia Among Young Adults with Type 1 Diabetes and Overweight or Obesity: Results from the Advancing Care for Type 1 Diabetes and Obes	45

A Randomized Crossover Pilot Study Evaluating Glucose Control During Exercise Initiated 1 or 2 h After a Meal in Adults with Type 1 Diabetes Treated with an Automated Insulin Delivery System	45
A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes	45
Continuous and Intermittent Glucose Monitoring in 2021	43
Software Packages and Tools for the Analysis of Continuous Glucose Monitoring Data	43
Insulin Delivery Hardware: Pumps and Pens	41
WITHDRAWN: Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial	39
Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes	38
Decision Support Tool for Self-Management of Insulin Dosing in Type 1 Diabetes with Multiple Daily Injections: A Proof-of-Concept Study	37
Developing and Evaluating a Natural Language Processing Algorithm to Detect Insulin Pump and Continuous Glucose Monitor Use in Electronic Health Records of Patients with Type 1 Diabetes	37
The Future of Dual Glucose–Ketone Monitoring in Youth with Diabetes	36
A Retrospective Real-Life Study to Compare Glycemic Control Between Simplified Meal Size Estimation and Precise Carbohydrates Counting in Type 1 Diabetes Patients Using DBLG1 Hybrid Closed-Loop System	36
Carbohydrate Counting/Bolus Calculator Mobile Application Improves Time in Range in Adults with Type 1 Diabetes Subjects	35
Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multicenter, Single-Arm, Feasibility Trial	35
Letter: Use of an Advanced Hybrid Closed-Loop Insulin Delivery System in a Hemodialysis Patient with Type 1 Diabetes and Anorexia Nervosa: A Case Report	35
Insulin Replacement Across the Menstrual Cycle in Women with Type 1 Diabetes: An In Silico Assessment of the Need for Ad Hoc Technology	34
Accuracy of Dexcom G6 Pro and G7 Continuous Glucose Monitors in Patients Treated with Maintenance Dialysis	34
Association Between Time in Range and Postprandial Glucose Contribution Rate in Non-Insulin-Treated Type 2 Diabetes Patients: Inverse Correlation of Time in Range with Postprandial Glucose Contributio	33
RESCUE Collaborative Community: A New Initiative to Reduce Rates of Intended Self-Injury and Suicide Among People with Diabetes	32
Glycemic Outcomes in Baseline Hemoglobin A1C Subgroups in the International Diabetes Closed-Loop Trial	32
Composite Metric of Glycemic Control Q-Score Is Elevated in Pediatric and Adolescent/Young Adult Hematopoietic Stem Cell Transplant Recipients	30
Mediating Effects of Technology-Based Therapy on the Relationship Between Socioeconomic Status and Glycemic Management in Pediatric Type 1 Diabetes	30
The Expanding Use of Continuous Glucose Monitoring in Type 2 Diabetes	30
Predicting Success with a First-Generation Hybrid Closed-Loop Artificial Pancreas System Among Children, Adolescents, and Young Adults with Type 1 Diabetes: A Model Development and Validation Study	29
FRONTIER—FreeStyle Libre System Use in Ontario Among People with Diabetes Mellitus in the IC/ES Database—Evidence from Real-World Practice: Patients Using Intensive Insulin	28
Age-Dependent Bolus Settings: Insulin-to-Carbohydrate Ratios and Insulin Sensitivity Factors in Pediatric Patients with Type 1 Diabetes on Conventional CSII in the DPV Registry	28
Use of Diabetes Technology at the Advanced Age	28
Contrasting Glycemic Outcomes in Young People with Diabetic Ketoacidosis at Onset of Type 1 Diabetes	27
Current Status and Emerging Options for Automated Insulin Delivery Systems	27
Clinical Trials in Diabetes: Examining the Value of Use of Continuous Dual Glucose-Ketone Monitoring	27
Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges	27
Online Classification of Unstructured Free-Living Exercise Sessions in People with Type 1 Diabetes	27
Advanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best Efficacy	27
Hybrid Closed Loop Systems Improve Glycemic Control and Quality of Life in Historically Minoritized Youth with Diabetes	27
Differences Between Glycemia Estimates from Hemoglobin A1c and Continuous Glucose Monitoring and Their Association with Complete Blood Counts	27
Cost–Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes	27
Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys	26
Lower Glycated Hemoglobin with Real-Time Continuous Glucose Monitoring Than with Intermittently Scanned Continuous Glucose Monitoring After 1 Year: The CORRIDA LIFE Study	26
Insulin Pump Infusion Set Failures Associated with Prolonged Hyperglycemia: Frequency and Relationship to Age and Type of Infusion Set During 22,741 Infusion Set Wears	26
Specialized Technology Education for Pumps and Pens in Underserved Populations with Diabetes	26
Late Afternoon Vigorous Exercise Increases Postmeal but Not Overnight Hypoglycemia in Adults with Type 1 Diabetes Managed with Automated Insulin Delivery	25
Review of Monogenic Diabetes: Clinical Features and Precision Medicine in Genetic Forms of Diabetes	25
COVID‐19 Pandemic and Diabetes Care	25
Continuous and Intermittent Glucose Monitoring in 2024	25
Time in Tight Range Versus Time in Range for Predicting Diabetic Retinopathy in Adults with Type 1 Diabetes Using Multiple Daily Insulin Injections: A Retrospective Longitudinal Study with isCGM Data	24
Advances in Exercise and Nutrition as Therapy in Diabetes	24
Continuous Glucose Monitoring Metrics and Continuous Glucose Monitoring–Based Hypoglycemia, Including Duration, in Individuals with Type 1 Diabetes Switching to Once-Weekly Insulin Icodec: A Post Hoc	24
Update on Management of Gestational Diabetes Mellitus and the Role of Continuous Glucose Monitor Technology	24
Diabetes Technology and Therapy in the Pediatric Age Group	24
Feasibility of Using a Factory-Calibrated Continuous Glucose Monitoring System to Diagnose Type 2 Diabetes	24
Technologies in Diabetes—the Sixteenth ATTD Yearbook	24

Impact of Missing Data on the Accuracy of Glucose Metrics from Continuous Glucose Monitoring Assessed Over a 2-Week Period	23
Real-World Effectiveness of the MiniMed™ 780G Advanced Hybrid Closed-Loop System for People ≥65 Years with Type 1 or Type 2 Diabetes in the United States	23
A Comparison of Continuous Glucose Monitoring Estimated Hemoglobin A1c in Adults with Type 1 or Type 2 Diabetes	23
New Medications for the Treatment of Diabetes	23
Risk Factor Analysis for Type 2 Diabetes Patients About Hypoglycemia Using Continuous Glucose Monitoring: Results from a Prospective Observational Study	23
MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks	23
Similar Time Course of Humoral Response to SARS-CoV-2 mRNA Vaccines in People With and Without Type 1 Diabetes	23
Anticipated Basal Insulin Reduction to Prevent Exercise-Induced Hypoglycemia in Adults and Adolescents Living with Type 1 Diabetes	23
Ranting in 2023: I Can't Make This Up	23
Are New Ultra-Rapid-Acting Insulins Associated with Improved Glycemic Control and Reduced Hypoglycemia in Comparison to Conventional Rapid-Acting Insulins for Individuals with Type 1 and Type 2 Diabet	22
Expert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens	22
Should We Bury HbA1c?	22
Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus	22
Insulin Pump Technology for Patients with Alcoholism: A Dangerous Combination or Worth a Try?	22
A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72	21
Primary Care and Diabetes Technologies and Treatments	21
Real-Time Continuous Glucose Monitoring Can Predict Severe Hypoglycemia in People with Type 1 Diabetes: Combined Analysis of the HypoDE and DIAMOND Trials	21
Emerging Trends in MAFLD and MASH	21
Re-Evaluating Inpatient Prandial Insulin Administration Timing: From Data to Clinical Practice	21
Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone	21
Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users	20
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes	20
Randomized, Crossover Trial of Control-IQ Technology with a Lower Treatment Range and a Modified Meal Bolus Module in Adults, Adolescents, Children, and Preschoolers with Varying Levels of Baseline Gl	19
Frequency of Rebound Hyperglycemia in Adults with Type 1 Diabetes Treated with Different Insulin Delivery Modalities	19
A Cure for Type 1 Diabetes: Are We There Yet?	19
Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes	19
Impact of Missed and Late Meal Boluses on Glycemic Outcomes in Automated Insulin Delivery-Treated Children and Adolescents with Type 1 Diabetes: A Two-Center, Population-Based Cohort Study	19
ATTD 2025 Invited Speaker Abstracts	19
Insulin Pump Infusion Set Failures Associated with Prolonged Hyperglycemia: Frequency and Relationship to Age and Type of Infusion Set During 22,741 Infusion Set Wears: Response to Letter to Editor	19
Clinical Utility of Serum C-Peptide Concentration for Hospitalized Patients with Hyperglycemia	19
Real‐World Diabetes Technology: What Do We Have? Who Are We Missing?	18
Primary Care and Diabetes Technologies and Treatments	18
Glucose and Psychosocial Outcomes 12 Months Following Transition from Multiple Daily Injections to Advanced Hybrid Closed Loop in Youth with Type 1 Diabetes and Suboptimal Glycemia	18
Feasibility of Closed-Loop Insulin Delivery with a Pregnancy-Specific Zone Model Predictive Control Algorithm	18
Aiming for the Best Glycemic Control Beyond Time in Range: Time in Tight Range as a New Continuous Glucose Monitoring Metric in Children and Adolescents with Type 1 Diabetes Using Different Treatment	18
Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor	18
Assessment of Glucose Monitoring Adherence in Medicare Beneficiaries with Insulin-Treated Diabetes	18
Automated Insulin Delivery Versus Standard of Care in the Management of People Living with Type 1 Diabetes and HbA1c <8%: A Cost–Utility Analysis in The Netherlands	18
Multivendor Continuous Glucose Monitor Integration into the Electronic Health Record: Real-World Experience of an Academic Pediatric Endocrinology Clinic	17
Glycemic Responses to Graded Exercise Testing in Adolescents Using Automated Insulin Delivery Systems	17
Nocturnal Hypoglycemia: Characterization with Continuous Glucose Monitoring in a Real-World Setting	17
Biases in Glucose Metrics Are Directly Related to Low Coverage of Continuous Glucose Monitoring: Insights from Diverse Populations	17
Accuracy of Continuous Glucose Monitoring in Adults with Type 1 Diabetes Admitted to Hospital: A Real-World Multicenter Observational Study	16
The Type 1 Diabetes and EXercise Initiative: Predicting Hypoglycemia Risk During Exercise for Participants with Type 1 Diabetes Using Repeated Measures Random Forest	16
Performance of the Dexcom G7 Continuous Glucose Monitoring System in Pregnant Women with Diabetes	16
Prevalence, Safety, and Metabolic Control Among Danish Children and Adolescents with Type 1 Diabetes Using Open-Source Automated Insulin Delivery Systems	16
Safety of Options to “Boost” (Enhancing Insulin Infusion Rates) and “Ease-Off” (Reducing Insulin Infusion Rates) in CamAPS FX Hybrid Closed-Loop System: A Real-World Analysis	16
ATTD 2025 Read By Title	16
Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies: An Evidence-Based Approach to Policymaking	16
Endocrine Management and Clinical Outcomes in a Cohort of Pediatric Patients Undergoing Total Pancreatectomy with Islet Autotransplantation	16
Transitioning from Self-Monitoring of Blood Glucose to Continuous Glucose Monitoring in Combination with a mHealth App Improves Glycemic Control in People with Type 1 and Type 2 Diabetes	16
Accuracy of a Real-Time Continuous Glucose Monitor in Pediatric Diabetic Ketoacidosis Admissions	16
Impact of Meal Insulin Bolus Timing and Bedtime Snacking on Continuous Glucose Monitoring–Derived Glycemic Metrics in Hospitalized Inpatients	16
Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?	16
Automated Insulin Delivery for Hypoglycemia Avoidance and Glucose Counterregulation in Long-Standing Type 1 Diabetes with Hypoglycemia Unawareness	16
A Telehealth Program Using Continuous Glucose Monitoring and a Connected Insulin Pen Cap in Nursing Homes for Older Adults with Insulin-Treated Diabetes: The Trescasas Study	16
The Virtual DCCT: Adding Continuous Glucose Monitoring to a Landmark Clinical Trial for Prediction of Microvascular Complications	15
Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5	15
Snapshot of CGM Metrics in Adolescents and Adults Achieving Target HbA1c Versus Those Not Meeting Target HbA1c	15
One-Year Follow-Up of Advanced Hybrid Closed-Loop System in Adults with Type 1 Diabetes Previously Naive to Diabetes Technology: The Effect of Switching to a Calibration-Free Sensor	15
The Virtual DCCT #3: Relationship of HbA1c and CGM Metrics with Cardiovascular Outcomes	15
Continuous Glucose Monitoring (CGM) Readings During Patient-Reported Symptomatic Hypoglycemia: Assessment of the Advanced Technologies and Treatments for Diabetes Consensus Definition of CGM-Recorded	15
Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study)	15
A Comparison of the Rates of Clock-Based Nocturnal Hypoglycemia and Hypoglycemia While Asleep Among People Living with Diabetes: Findings from the Hypo-METRICS Study	15
Virtual Clinics for Diabetes Care	15
Changes in HbA1c Between 2011 and 2017 in Germany/Austria, Sweden, and the United States: A Lifespan Perspective	15
Comment on “Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes” by Messer et al.	15
Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia	14
MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience	14
Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Perinatal Complications	14
Which Treatment Modalities Are Being Used by Italian Children and Adolescents with Type 1 Diabetes?	14
Telemetric Continuous Glucose Monitoring During the COVID-19 Pandemic in Isolated Hospitalized Patients in Denmark: A Randomized Controlled Exploratory Trial	14
Virtual Clinics for Diabetes Care	14
Recent Improvements in Attainment of the Hemoglobin A1c Target of ≤7.0% Among Adults with Type 1 Diabetes in Ontario: A Retrospective Cohort Study	14
Artificial Pancreas: The First 20 Years*	14
Beyond Glucose Monitoring: Multianalyte Sensor Use in Diabetes	14
Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System	14
Technology Utilization in Black Adolescents with Type 1 Diabetes: Exploring the Decision-Making Process	14
Temporary Target Versus Suspended Insulin Infusion in Patients with Type 1 Diabetes Using the MiniMed 780G Advanced Closed-Loop Hybrid System During Aerobic Exercise: A Randomized Crossover Clinical T	14
Assessment of a Decision Support System for Adults with Type 1 Diabetes on Multiple Daily Insulin Injections	13

Identifying Continuous Glucose Monitoring Data Using Machine Learning	13
Limitations of Reporting Time Below Range as a Percentage	13
Insulin Pump Use and Diabetic Ketoacidosis Risk in Type 1 Diabetes: Secular Trends over Four Decades	13
Shining the Spotlight on Multiple Daily Insulin Therapy: Real-World Evidence of the InPen Smart Insulin Pen	13
Automated Insulin Delivery Around Exercise in Adults with Type 1 Diabetes: A Pilot Randomized Controlled Study	13
New Insulins, Biosimilars, and Insulin Therapy	13
Historical Insights and Current Perspectives on the Diagnosis and Management of Presymptomatic Type 1 Diabetes	13
A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70–180 mg/dL Versus Time-in-Tight-Range 70–140 mg/dL	13
Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems	13
Letter: “Nocturnal Hypoglycemia: Characterization with Continuous Glucose Monitoring in a Real-World Setting”	13
Real-World Insulin Treatment in Pregnant Women with Type 1 Diabetes Using an Advanced Hybrid Closed-Loop System	13
Hemorrhagic Shock Associated with a Subcutaneous Insulin Pump Catheter: First Time Reported Side Effect	13
Continuous Glucose Monitoring Metrics and Hemoglobin A1c Relationship in Patients with Type 2 Diabetes Treated by Hemodialysis	12
Insulin Delivery Hardware: Pumps and Pens	12
Assessing the Accuracy of Continuous Glucose Monitoring Metrics: The Role of Missing Data and Imputation Strategies	12
Use of Technologies at the Advanced Age	12
Continuous Glucose Monitoring-Derived Glucometrics in Adults with Type 1 Diabetes When Switching Basal Insulins	12
Expert Guidance on Off-Label Use of Hybrid Closed-Loop Therapy in Pregnancies Complicated by Diabetes	11
Personalized Hemoglobin A1c Shows Better Correlation with Mean Glucose than Laboratory Hemoglobin A1c in Ugandan Youth with Type 1 Diabetes, but Mean Glucose Is Not Clinically Useful in This Populatio	11
Important Decrease in Hospitalizations for Acute Diabetes Events Following FreeStyle Libre System Initiation in People with Type 2 Diabetes on Basal Insulin Therapy in France	11
The Type of Patient Training Does Not Impact Outcomes in the First 90 Days of Automated Insulin Delivery Use	11
Real-World Safety and Effectiveness of U200 Insulin Use in Automated Insulin Delivery Systems in Adolescents and Young Adults with Type 1 Diabetes	11
Accuracy of FreeStyle Libre 3 During Moderate-Intensity Continuous Aerobic Exercise at Different Phases of the Menstrual Cycle in Females with Type 1 Diabetes	11
Impact of Age at Diagnosis and Insulin Delivery Modality on Free-Living Glycemia in Type 1 Diabetes During Periods Associated with Dysglycemia: A Retrospective Analysis of the Type 1 Diabetes Exercise	11
Continuous Glucose Monitoring and Long-Term Assessment of Islet Function in Autologous Islet Transplantation after Total Pancreatectomy for Neoplasm: Preliminary Insights from a Prospective Study	11
ATTD 2022 Abstract Author Index	11
Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin	11
A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts	11
The Advanced Hybrid Closed Loop Improves Glycemia Risk Index, Continuous Glucose Monitoring Index, and Time in Range in Children with Type 1 Diabetes: Real-World Data from a Single Center Study	11
Does Combining a Mobile Dose Calculation App with a Continuous Insulin Infusion System Improve Glycemic Control and Quality of Life Compared with a Hybrid System in Patients with Type 1 Diabetes? A De	11
Global Burden of Diabetic Ketoacidosis	11
International Consensus of Continuous Glucose Monitor Use in Pharmacological Clinical Trials in Diabetes	11
Closed-Loop Insulin Delivery Effects on Glycemia During Sleep and Sleep Quality in Older Adults with Type 1 Diabetes: Results from the ORACL Trial	11
Diabetes Technology in the Hospital	11
Continuous Glucose Monitoring for Type 2 Diabetes: How Does It Compare with Type 1 Diabetes?	11
Real-World Evaluation of Artificial Intelligence-Based Diabetic Retinopathy Screening Using the Optomed Aurora Handheld Fundus Camera	11